NVTIA® Ergothioneine for Healthy Aging and Skin Health

Sponsor
EUROPEAN LIFE SCIENCE RESEARCH ASSOCIATION
Study ID
NCT07750002
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Aging
  • Oxidative Stress
  • Skin Aging

Eligibility Criteria

Sex
ALL
Age
35 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • NVTIA® Ergothioneine — DIETARY_SUPPLEMENT
    NVTIA® Ergothioneine is a standardized branded ergothioneine ingredient manufactured under controlled quality standards for use as a dietary supplement.
  • Placebo — OTHER
    Matching placebo capsules identical in appearance, color, size, and packaging to the investigational product. One capsule will be administered orally once daily for 12 weeks.

Study Details

This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of NVTIA® Ergothioneine, a branded ergothioneine ingredient, on healthy aging biomarkers and skin health in healthy adults aged 40 to 65 years. Participants will receive either NVTIA® Ergothioneine or a matching placebo once daily for 12 weeks. The primary objective of this study is to evaluate the effects of NVTIA® Ergothioneine supplementation on biomarkers associated with oxidative stress and healthy aging. Secondary objectives include assessment of skin elasticity, skin hydration, inflammatory biomarkers, and overall safety. The findings of this study are expected to provide clinical evidence supporting the role of NVTIA® Ergothioneine in promoting healthy aging and maintaining skin health.

Key Dates

First listed
Aug 6, 2026
Start date
Aug 15, 2026
Status verified
Aug 2026
Primary completion
Oct 16, 2026
Completion
Apr 8, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: NVTIA® Ergothioneine
    Participants will receive capsules containing NVTIA® Ergothioneine, providing 30 mg ergothioneine once daily for 12 weeks.
  • Placebo Comparator: Placebo
    Participants will receive matching placebo capsules identical in appearance to the investigational product once daily for 12 weeks.

Primary Outcome Measure

Change in Plasma 8-Hydroxy-2'-deoxyguanosine (8-OHdG) [ Time Frame: Baseline and Week 12 ]

Central Contacts

Related Studies